2024 Annual Meeting | C35 - Treatment of Pediatric Multiple Sclerosis in the Current Era

Date Sunday 04/14/24

Time 07:00 AM - 09:00 AM MDT Add To Calendar

Location Colorado Convention Center | Mile High 4CD

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Jennifer Graves, MD, PhD

Topic(s) Child Neurology and Developmental Neurology, Multiple Sclerosis

Learning Objectives Participants should be able to understand the approach to the diagnosis of pediatric MS and unique features of the disease in children; summarize current literature regarding treatments for acute relapses and for disease modulation; and address symptomatic management, cognitive symptoms, mental wellness and physical activity, and strategies for rehabilitation.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:50 AM MDT	Speaker	Unique Features of Pediatric MS and Updates in Treatment Approaches Jennifer Graves, MD, PhD
07:50 AM - 08:40 AM MDT	Speaker	Neurocognitive Aspects of Pediatric MS and Their Management Lauren B. Krupp, MD, FAAN
08:40 AM - 09:00 AM MDT	Q&A	Faculty Discussion, Questions, & Answers Jennifer Graves, MD, PhD, Lauren B. Krupp, MD, FAAN

Faculty Disclosures
Jennifer Graves, MD, PhD	Dr. Graves has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Graves has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Graves has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MSJ. The institution of Dr. Graves has received research support from Octave. The institution of Dr. Graves has received research support from Sanofi. The institution of Dr. Graves has received research support from EMD Serono.
Lauren B. Krupp, MD, FAAN	Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lerhman. Dr. Krupp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for medscape. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NeuroLive. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Krupp has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Cleveland Clinic. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for MCIC. The institution of Dr. Krupp has received research support from Biogen. The institution of Dr. Krupp has received research support from National Multiple Sclerosis Society. Dr. Krupp has received intellectual property interests from a discovery or technology relating to health care.